Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $10.20
  • 50 Day Moving Average: $9.15
  • 200 Day Moving Average: $7.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.35
  • P/E Growth: -4.27
  • Market Cap: $1.98B
  • Outstanding Shares: 192,713,000
  • Beta: 2
Additional Links:
Companies Related to Ariad Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $9.29 (9.41% downside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateFirmActionRatingPrice TargetDetails
7/31/2016Cowen and CompanyReiterated RatingOutperform$10.00View Rating Details
7/29/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details
7/29/2016Barclays PLCBoost Price TargetUnderweight$8.00 -> $9.00View Rating Details
6/20/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details
6/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
5/24/2016William BlairReiterated RatingBuy$10.00View Rating Details
3/11/2016JPMorgan Chase & Co.Reiterated RatingOutperform$11.00 -> $9.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$7.00 -> $5.00View Rating Details
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details
12/11/2014Credit Suisse Group AGDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216($0.11)$0.59$60.64 million$65.30 millionViewListenView Earnings Details
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details
11/3/2011$0.02$0.10ViewN/AView Earnings Details
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
Current Year EPS Consensus Estimate: $-0.08 EPS
Next Year EPS Consensus Estimate: $-0.48 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20162($0.22)($0.21)($0.22)
Q4 20162($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)


Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/22/2016Timothy P ClacksonInsiderSell19,436$10.47$203,494.92View SEC Filing  
8/12/2016Timothy P ClacksonInsiderSell25,000$10.50$262,500.00View SEC Filing  
7/22/2016Timothy P ClacksonInsiderSell18,286$8.11$148,299.46View SEC Filing  
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
News IconAriad Pharmaceuticals Inc.'s (ARIA): Sizzling Stock - Hot Stocks Point (NASDAQ:ARIA) - August 25 at 8:23 AM
News IconInsider Trading and Recommendation Review: Ariad ... - Post Registrar (NASDAQ:ARIA) - August 25 at 8:23 AM logoMomentum Stocks: Rowan Companies plc (RDC), Ariad Pharmaceuticals Inc. (ARIA), Tiffany & Co. (TIF) - iStreetWire (NASDAQ:ARIA) - August 24 at 3:35 PM logoUptrend Call Working As Ariad Pharmaceuticals Stock Rises 30.1% (ARIA) (NASDAQ:ARIA) - August 24 at 11:49 AM logoETF’s with exposure to ARIAD Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:ARIA) - August 24 at 11:49 AM
News IconTrading the Biotech News: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) - August 23 at 3:35 PM logoARIAD Pharmaceuticals Could Be Benefiting From Prescriber Education - Seeking Alpha (NASDAQ:ARIA) - August 23 at 7:25 AM logoARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ARIA) - August 22 at 8:41 PM logoBiotechs Rise on Bet Medivation Losers Will Look to Next Deal (NASDAQ:ARIA) - August 22 at 3:36 PM
News IconNews review of 2 biotech stocks: Alexion Pharmaceuticals (NASDAQ:ALXN), Ariad Pharmaceuticals (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) - August 19 at 11:56 AM logoResearch Report on Biotech Equities -- Gilead Sciences, Exelixis ... - PR Newswire (press release) (NASDAQ:ARIA) - August 19 at 11:56 AM
News IconTrading the Biotech News: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Novavax, Inc. (NASDAQ:NVAX) - The Voice Registrar (NASDAQ:ARIA) - August 18 at 3:42 PM logoARIAD PHARMACEUTICALS INC Financials (NASDAQ:ARIA) - August 17 at 3:37 PM logo32.2% Return Seen to Date on SmarTrend Ariad Pharmaceuticals Call (ARIA) (NASDAQ:ARIA) - August 16 at 8:53 PM
News IconBiotech Stocks To Put On Your Watch List: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Galena Biopharma, Inc ... - The Voice Registrar (NASDAQ:ARIA) - August 16 at 3:38 PM
News IconHot Biotech Stocks Recap: Galena Biopharma, Inc. (NASDAQ:GALE ... - The Voice Registrar (NASDAQ:ARIA) - August 15 at 9:06 PM logoWill ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Hit $13 Price Target? - Investor Newswire (NASDAQ:ARIA) - August 15 at 3:38 PM logoAriad Is Worth A Look After Q2 Results - Seeking Alpha (NASDAQ:ARIA) - August 13 at 3:34 PM
News IconBiotech Stocks To Put On Your Watch List: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Medivation, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:ARIA) - August 12 at 12:10 PM
News IconTop Earnings to Watch for: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:ARIA) - August 11 at 3:39 PM logoWatch These 7 Huge Call Purchases In Tuesday Trade - Benzinga (NASDAQ:ARIA) - August 9 at 10:12 PM logoAriad Pharmaceuticals Inc. (NASDAQ:ARIA) Insider Activities Are in the Air - Review Fortune (NASDAQ:ARIA) - August 9 at 10:12 PM logoWhy There Is Upside for Incyte Despite Recent Selloff (NASDAQ:ARIA) - August 9 at 4:41 PM logoTop Buys by Top Brass: CEO Panayiotopoulos's $200K Bet on ARIA (NASDAQ:ARIA) - August 8 at 9:01 PM
News IconAcute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Pipeline 2016 Market Review Research (NASDAQ:ARIA) - August 8 at 9:01 PM logoARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ARIA) - August 8 at 9:01 PM
News IconHealthcare Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Progenics Pharmaceuticals (NASDAQ:PGNX) - TWN (NASDAQ:ARIA) - August 8 at 3:37 PM logoETF’s with exposure to ARIAD Pharmaceuticals, Inc. : August 8, 2016 (NASDAQ:ARIA) - August 8 at 3:37 PM
News IconStock-research Ratings: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), MetLife, Inc. (NYSE:MET) - TWN (NASDAQ:ARIA) - August 5 at 3:35 PM logoARIAD Pharmaceuticals, Inc. :ARIA-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 (NASDAQ:ARIA) - August 5 at 11:59 AM logo3 Notable Runners: Western Digital Corporation (WDC), Ariad Pharmaceuticals Inc. (ARIA), Staples, Inc. (SPLS) - iStreetWire (NASDAQ:ARIA) - August 4 at 9:20 PM
News IconAnalyst Research and Ratings: Allegheny Technologies Inc. (NYSE:ATI), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Wellesleys News (NASDAQ:ARIA) - August 3 at 3:38 PM
News IconStocks Roundup: Bonanza Creek Energy Inc (NYSE:BCEI), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - NYSE Journal (press release) (NASDAQ:ARIA) - August 3 at 3:38 PM logoTwo Buzzers within Analysts Radar: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Alexion Pharmaceuticals, Inc ... - Street Updates (NASDAQ:ARIA) - August 3 at 3:38 PM
News IconStock's Buzzers: Wells Fargo & Co (NYSE:WFC), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - NYSE Journal (press release) (NASDAQ:ARIA) - August 2 at 3:36 PM logoAnalyst Ratings Worth Watching: Evoke Pharma Inc (NASDAQ:EVOK), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - Review Fortune (NASDAQ:ARIA) - August 1 at 3:32 PM logoAriad Pharmaceuticals, Inc. (ARIA) Continues to Look Compelling, Says Cowen (NASDAQ:ARIA) - July 29 at 9:03 PM logoCurrent Analysts Rating Update: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Alexion Pharmaceuticals, Inc ... - Street Updates (NASDAQ:ARIA) - July 29 at 3:34 PM logoAriad Pharmaceuticals, Inc. (ARIA) Continues to Look Compelling, Says Cowen - Smarter Analyst (NASDAQ:ARIA) - July 29 at 3:34 PM logoARIAD's (ARIA) Stock Up on Q2 Earnings & Revenue Beat (NASDAQ:ARIA) - July 29 at 9:52 AM logoWhy Ariad Pharmaceuticals Shares Jumped 12.5% Today (NASDAQ:ARIA) - July 28 at 6:28 PM logoAnalysts Spotlight: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Street Updates (NASDAQ:ARIA) - July 28 at 4:35 PM logoAriad Pharmaceuticals Inc Q2 Profit Advances 117% - Nasdaq (NASDAQ:ARIA) - July 28 at 4:35 PM logoAriad Pharmaceuticals, Inc.: ARIA Stock Squeezes the Shorts on Blowout Quarter (NASDAQ:ARIA) - July 28 at 12:18 PM logoAriad Pharmaceuticals : beats 2Q profit forecasts (NASDAQ:ARIA) - July 28 at 12:18 PM logoAriad Pharmaceuticals Inc Q2 Profit Advances 117% (NASDAQ:ARIA) - July 28 at 12:18 PM logoARIAD (ARIA) Swings to Earnings in Q2, Revenues Beat (NASDAQ:ARIA) - July 28 at 9:12 AM logoAriad beats 2Q profit forecasts (NASDAQ:ARIA) - July 28 at 8:56 AM logoAriad Pharmaceuticals Inc. (NASDAQ:ARIA) Earns Consensus Hold Rating - Review Fortune (NASDAQ:ARIA) - July 27 at 3:34 PM logoWatch for Drug Stocks Earnings on Jul 28: BMY, CELG & More (NASDAQ:ARIA) - July 27 at 9:47 AM


Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff